Gene · 64783
Papers2,224
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,224
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The roles of m6A methylation in cervical cancer: functions, molecular mechanisms, and clinical applications. | Cell Death Dis | 2023 | 37951987 | PubTator, text mining | PubMed |
| Congenital leukemia: A case report and review of literature. | World J Clin Cases | 2023 | 37946786 | PubTator, text mining | PubMed |
| Identification of m6A-associated genes as prognostic and immune-associated biomarkers in Wilms tumor. | Discov Oncol | 2023 | 37938417 | PubTator, text mining | PubMed |
| Pancancer analysis of the correlations of HS6ST2 with prognosis, tumor immunity, and drug resistance. | Sci Rep | 2023 | 37932473 | PubTator, text mining | PubMed |
| Significance of RNA N6-methyladenosine regulators in the diagnosis and subtype classification of coronary heart disease using the Gene Expression Omnibus database. | Front Cardiovasc Med | 2023 | 37928762 | PubTator, text mining | PubMed |
| METTL16 Inhibits the Malignant Progression of Epithelial Ovarian Cancer through the lncRNA MALAT1/β-Catenin Axis. | Anal Cell Pathol (Amst) | 2023 | 37927399 | PubTator, text mining | PubMed |
| The emerging roles of N6-methyladenosine RNA modifications in thyroid cancer. | Eur J Med Res | 2023 | 37915103 | PubTator, text mining | PubMed |
| Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer. | J Transl Med | 2023 | 37915034 | PubTator, text mining | PubMed |
| Resveratrol affects ccRCC cell senescence and macrophage polarization by regulating the stability of CCNB1 by RBM15. | Epigenomics | 2023 | 37909116 | PubTator, text mining | PubMed |
| Circular RNA cFAM210A, degradable by HBx, inhibits HCC tumorigenesis by suppressing YBX1 transactivation. | Exp Mol Med | 2023 | 37907737 | PubTator, text mining | PubMed |
| GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer. | Cancer Cell Int | 2023 | 37904122 | PubTator, text mining | PubMed |
| N6-Methyladenosine (m6A) Modification in Natural Immune Cell-Mediated Inflammatory Diseases. | J Innate Immun | 2023 | 37903470 | PubTator, text mining | PubMed |
| Emerging roles of interactions between ncRNAs and other epigenetic modifications in breast cancer. | Front Oncol | 2023 | 37901333 | PubTator, text mining | PubMed |
| Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review. | Front Genet | 2023 | 37886684 | PubTator, text mining | PubMed |
| RNA modification in cardiovascular disease: implications for therapeutic interventions. | Signal Transduct Target Ther | 2023 | 37884527 | PubTator, text mining | PubMed |
| Dynamic characterization and interpretation for protein-RNA interactions across diverse cellular conditions using HDRNet. | Nat Commun | 2023 | 37884495 | PubTator, text mining | PubMed |
| N6-methyladenosine methylation in kidney injury. | Clin Epigenetics | 2023 | 37865763 | PubTator, text mining | PubMed |
| PIK3CD correlates with prognosis, epithelial-mesenchymal transition and tumor immune infiltration in breast carcinoma. | Discov Oncol | 2023 | 37861728 | PubTator, text mining | PubMed |
| m6A reading protein RBMX as a biomarker for prognosis and tumor progression in esophageal cancer. | Transl Cancer Res | 2023 | 37859733 | PubTator, text mining | PubMed |
AZGP1P2/UBA1/RBM15 Cascade Mediates the Fate Determinations of Prostate Cancer Stem Cells and Promotes Therapeutic Effect of Docetaxel in Castration-Resistant Prostate Cancer via TPM1 m6A Modification. | Research (Wash D C) | 2023 | 37854295 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64783/papers?page=12